CoChat

A comprehensive review on the efficacy of S-Adenosyl-L-methionine in Major Depressive Disorder.

De Berardis, Domenico, Orsolini, Laura, Serroni, Nicola, Girinelli, Gabriella, Iasevoli, Felice, Tomasetti, Carmine, de Bartolomeis, Andrea, Mazza, Monica, Valchera, Alessandro, Fornaro, Michele, Perna, Giampaolo, Piersanti, Monica, Di Nicola, Marco, Cavuto, Marilde, Martinotti, Giovanni, Di Giannantonio, Massimo · 2016 · CNS & Neurological Disorders - Drug Targets
Cited by 70

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To review the antidepressant efficacy of S-Adenosyl-L-Methionine (SAMe) both in monotherapy and/or in augmentation with antidepressants to better understand its potential role in the treatment of patients with Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). DATA SOURCES: A MEDLINE/PubMed search was carried out by using the following set of keywords: ((SAMe OR SAdenosyl- L-Methionine) AND (major depressive disorder OR depression)). Data Selection and Data Extraction: No language or time restrictions were placed on the electronic searches. Randomized controlled trials and open trials involving humans were here included and analyzed. The references of published articles identified in the initial search process were also examined for any additional studies appropriate for the review. DATA SYNTHESIS: SAMe is an important physiologic compound, playing a central role as precursor molecule in several biochemical reactions. Numerous studies have shown that SAMe may affect the regulation of various critical components of monoaminergic neurotransmission involved in the pathophysiology of MDD. Some findings have suggested its antidepressant efficacy in treating MDD. Several randomized controlled trials have supported that the antidepressant efficacy of SAMe in monotherapy is superior to placebo and tricyclic antidepressants. Recent findings have also demonstrated its efficacy in patients nonresponsive to selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. CONCLUSION: Overall, SAMe is a well-tolerated medication, which may offer considerable advantages as an alternative to antidepressant drugs or as an add-on therapy in the treatment of MDD and TRD. More large-scale controlled trials are needed to gain a better understanding of the relative efficacy of this drug.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1871527314666150821103825

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 70

Metadata

Authors
De Berardis, D., Orsolini, L., Serroni, N., Girinelli, G., Iasevoli, F., Tomasetti, C., de Bartolomeis, A., Mazza, M., Valchera, A., Fornaro, M., Perna, G., Piersanti, M., Di Nicola, M., Cavuto, M., Martinotti, G., & Di Giannantonio, M.
Venue
CNS & Neurological Disorders - Drug Targets
Published
2016-01-15
Volume
15
Issue
1
Pages
35-44
ISSN
  • 1568-007X (ISSN-L)
  • 1871-5273
OpenAlex
W2291361311
Cited by
70
References
10
FWCI
4.08
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A comprehensive review on the efficacy of S-Adenosyl-L-methionine in Major Depressive Disorder. https://app.cochat.ai/papers/10.2174/1871527314666150821103825
The paper
De Berardis, D., Orsolini, L., Serroni, N., Girinelli, G., Iasevoli, F., Tomasetti, C., de Bartolomeis, A., Mazza, M., Valchera, A., Fornaro, M., Perna, G., Piersanti, M., Di Nicola, M., Cavuto, M., Martinotti, G., & Di Giannantonio, M. (2016). A comprehensive review on the efficacy of S-Adenosyl-L-methionine in Major Depressive Disorder. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/1871527314666150821103825

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.